WallStreetZenWallStreetZen

NASDAQ: SAGE
Sage Therapeutics Inc Stock

$21.77-0.09 (-0.41%)
Updated Mar 4, 2024
SAGE Price
$21.77
Fair Value Price
N/A
Market Cap
$1.31B
52 Week Low
$16.52
52 Week High
$59.99
P/E
-2.41x
P/B
1.64x
P/S
15x
PEG
N/A
Dividend Yield
N/A
Revenue
$86.46M
Earnings
-$541.49M
Gross Margin
97.5%
Operating Margin
-626.32%
Profit Margin
-626.3%
Debt to Equity
0.1
Operating Cash Flow
-$541M
Beta
1.14
Next Earnings
Apr 30, 2024
Ex-Dividend
N/A
Next Dividend
N/A

SAGE Overview

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SAGE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SAGE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SAGE is good value based on its book value relative to its share price (1.64x), compared to the US Biotechnology industry average (6.2x)
P/B vs Industry Valuation
SAGE is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SAGE due diligence checks available for Premium users.

Be the first to know about important SAGE news, forecast changes, insider trades & much more!

SAGE News

Valuation

SAGE fair value

Fair Value of SAGE stock based on Discounted Cash Flow (DCF)
Price
$21.77
Fair Value
-$0.05
Undervalued by
47,255.45%
SAGE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

SAGE price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.41x
Industry
15.95x
Market
36.03x

SAGE price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.64x
Industry
6.2x
SAGE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SAGE's financial health

Profit margin

Revenue
$78.0M
Net Income
-$32.7M
Profit Margin
-41.9%
SAGE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SAGE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$882.3M
Liabilities
$82.7M
Debt to equity
0.1
SAGE's short-term assets ($869.35M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SAGE's short-term assets ($869.35M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SAGE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SAGE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$119.5M
Investing
$42.1M
Financing
-$262.0k
SAGE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SAGE vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
SAGE$1.31B-0.41%-2.41x1.64x
ADMA$1.31B+3.62%-44.00x9.66x
AMLX$1.30B+2.30%26.22x2.99x
VERV$1.32B-2.76%-5.08x2.21x
ETNB$1.29B+9.11%-6.89x2.40x

Sage Therapeutics Stock FAQ

What is Sage Therapeutics's quote symbol?

(NASDAQ: SAGE) Sage Therapeutics trades on the NASDAQ under the ticker symbol SAGE. Sage Therapeutics stock quotes can also be displayed as NASDAQ: SAGE.

If you're new to stock investing, here's how to buy Sage Therapeutics stock.

What is the 52 week high and low for Sage Therapeutics (NASDAQ: SAGE)?

(NASDAQ: SAGE) Sage Therapeutics's 52-week high was $59.99, and its 52-week low was $16.52. It is currently -63.71% from its 52-week high and 31.82% from its 52-week low.

How much is Sage Therapeutics stock worth today?

(NASDAQ: SAGE) Sage Therapeutics currently has 60,106,687 outstanding shares. With Sage Therapeutics stock trading at $21.77 per share, the total value of Sage Therapeutics stock (market capitalization) is $1.31B.

Sage Therapeutics stock was originally listed at a price of $30.10 in Jul 18, 2014. If you had invested in Sage Therapeutics stock at $30.10, your return over the last 9 years would have been -27.67%, for an annualized return of -3.54% (not including any dividends or dividend reinvestments).

How much is Sage Therapeutics's stock price per share?

(NASDAQ: SAGE) Sage Therapeutics stock price per share is $21.77 today (as of Mar 4, 2024).

What is Sage Therapeutics's Market Cap?

(NASDAQ: SAGE) Sage Therapeutics's market cap is $1.31B, as of Mar 5, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Sage Therapeutics's market cap is calculated by multiplying SAGE's current stock price of $21.77 by SAGE's total outstanding shares of 60,106,687.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.